Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02107235 · ClinicalTrials.gov registry record · Phase 1
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
A Phase 1 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02107235 is a Phase 1 study that has completed, run by Traws Pharma. The registered enrollment target is 2 participants.
The verdict
NCT02107235, a Phase 1 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck Squamous Cell Carcinoma. This study will determine the highest safe dose of oral rigosertib that can be used with cisplatin and CRT. This study will also record any side effects that may occur and measure tumor sizes and how long patients live.
Interventions
- RADIATION Radiotherapy
- DRUG cisplatin
- DRUG oral rigosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02107235
The ClinicalTrials.gov registry entry for NCT02107235 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiotherapy is the first listed.
NCT02107235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02107235 about?
NCT02107235 is a clinical study titled "Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer". The working hypothesis is that oral rigosertib treatment when added to platinum-based Chemoradiotherapy (CRT) will improve progression-free survival for first-line patients with intermediate- or high-risk human papillomavirus negative positive (HPV (+)) Head and Neck Squamous Cell Carcinoma. This st...
What is the current status of trial NCT02107235?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02107235?
The interventions under investigation include: Radiotherapy (RADIATION), cisplatin (DRUG), oral rigosertib (DRUG).
Who is sponsoring clinical trial NCT02107235?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.